GSK Bio
NEWS
Healthcare companies are now looking at pharma executives for leadership roles as the landscape of healthcare is dramatically changing.
GlaxoSmithKline has decided not to make a play for Pfizer’s consumer health business. The decision came one day after another potential suitor walked away from a potential deal.
Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business.
In BioSpace’s Ideal Employer Survey GSK came in at #12 overall in the survey rankings.
The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent.
AMO Pharma reported that patients treated with its Phase II neuromuscular treatment for onset myotonic dystrophy type 1 experienced clinical benefits such as an improvement in cognitive function and an increased ability to perform daily tasks.
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
JOBS
IN THE PRESS